Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ana Candalija


Postdoctoral Researcher

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two tightly connected neurodegenerative diseases overlapping in clinical, pathological and genetic features. Mutations in more than 25 genes have been suggested to cause ALS/FTD, including G4C2 hexanucleotide repeat expansions in the C9orf72 gene, which is the most frequent cause of ALS (40% fALS, 7% sALS cases) and FTD (20% familial cases). Pathogenic mechanisms leading to neurodegeneration in these patients are currently unknown but three hypotheses have been proposed: the toxic accumulation of (G4C2)n‑rich RNA transcripts, the non-canonical repeat-associated non-ATG (RAN) translation producing dipeptide polymers prone to aggregation, and finally the loss of function of the C9orf72 protein.

My research is focused in determine the effector pathways leading to neurodegeneration in C9orf72 ALS/FTD by using pure FACS-isolated motor neurons from iPSC from C9orf72 patients. Transcriptomic analysis of these motor neurons and gene overexpression/knock down of the selected effectors will be carried out for this purpose. The identified effectors will be tested as targets for pharmacological therapy in a zebrafish model of G4C2-linked ALS/FTD.